2024
Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial
Balter D, Puglisi L, Dziura J, Fiellin D, Howell B. Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial. Journal Of Substance Use And Addiction Treatment 2024, 164: 209438. PMID: 38857827, PMCID: PMC11300157, DOI: 10.1016/j.josat.2024.209438.Peer-Reviewed Original ResearchXR-NTXBuprenorphine-naloxoneOpioid use disorderCriminal legal involvementUse disorderHazard of overdoseLifetime incarcerationLegal involvementOpioid use disorder treatment outcomesPer-protocol analysisExtended-release naltrexoneMOUD effectivenessTreatment outcomesEffects of medicationHazard of relapseSecondary analysisIntention-to-treat analysisIntention-to-treatRandomized controlled trialsEffects of MOUDRelapseControlled trialsDisordersOpioidPotential effect modifiers
2023
Health Insurance and Mental Health Treatment Use Among Adults With Criminal Legal Involvement After Medicaid Expansion
Howell B, Hawks L, Balasuriya L, Chang V, Wang E, Winkelman T. Health Insurance and Mental Health Treatment Use Among Adults With Criminal Legal Involvement After Medicaid Expansion. Psychiatric Services 2023, 74: 1019-1026. PMID: 37016823, PMCID: PMC10939137, DOI: 10.1176/appi.ps.20220171.Peer-Reviewed Original ResearchConceptsHealth insurance coverageMental disordersMedicaid expansionSubstance useInsurance coverageTreatment useMental health treatment useAffordable Care Act Medicaid expansionMental health treatmentSubstance use disordersFederal poverty levelUse of treatmentsLegal involvementLow health insurance coverageNSDUH respondentsUse disordersHealth treatmentDrug useMental illnessPercentage point increaseAge 18Insurance accessDisordersHealth insuranceTreatment